Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia

Jiang,Min; Zou,Xueqin; Lu,Lingyun

doi:10.3892/or.2018.6917

Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia

Authors:
- Min Jiang
- Xueqin Zou
- Lingyun Lu
View Affiliations

Affiliations: Department of Pediatrics, The Fifth Hospital of Xiamen, Tongmin Branch of The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361101, P.R. China, Department of Internal Medicine, The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, Yichang, Hubei 443003, P.R. China, Department of Orthopedics, The Fifth Hospital of Xiamen, Tongmin Branch of The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361101, P.R. China
Published online on: December 7, 2018 https://doi.org/10.3892/or.2018.6917
Pages: 885-894
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute B‑cell lymphoblastic leukemia (B‑ALL) is a common type of blood cancer, which is associated with aberrant gene expression. Cytokine receptor‑like factor 2 (CRLF2) serves a crucial role in the growth and allergic and inflammatory responses of dendritic cells and T cells. The purpose of the present study was to investigate the potential therapeutic and prognostic effect of silencing the CRLF2‑mediated RAC‑α serine/threonine‑protein kinase (AKT)/serine/threonine‑protein kinase mTOR (mTOR) pathway in B‑ALL. In our study, bone marrow specimens were collected from 128 children with B‑ALL and 26 healthy children. The expression of CRLF2 in bone marrow tissue was detected using immunohistochemistry. The survival rates were compared among the children with high and low CRLF2 expression levels. BaF3 leukemia cells were treated with CRLF2 short hairpin RNA knockdown and/or the AKT/mTOR pathway specific inhibitor LY294002. mRNA and protein expression associated with CRLF2 and the AKT/mTOR pathway in each group was detected by reverse transcription‑quantitative polymerase chain reaction analysis and western blotting. The viability of BaF3 cells in all the groups was assessed by Cell Counting Kit‑8 assay; the migration and invasion of BaF3 cells were determined by wound healing and Transwell invasion assays; and the sensitivity of BaF3 cells to the chemotherapeutic drug imatinib was detected using flow cytometry. The results demonstrated that CRLF2 overexpression is associated with a poor prognosis in B‑ALL, and the CRLF2/AKT/mTOR pathway is involved in the migration, invasion and chemotherapeutic agent‑induced apoptosis of BaF3 cells.

View Figures

View References

1	Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, Pieters R, Korbijn CM, Silverman LB, Schmiegelow K, et al: Acute lymphoblastic leukemia in children with down syndrome: A retrospective analysis from the Ponte di Legno study group. Blood. 123:70–77. 2014. View Article : Google Scholar : PubMed/NCBI
2	Tasian SK, Doral MY, Borowitz MJ, Wood BL, Chen IM, Harvey RC, Gastier-Foster JM, Willman CL, Hunger SP, Mullighan CG, et al: Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood. 120:833–842. 2012. View Article : Google Scholar : PubMed/NCBI
3	Maude S, Tasian S, Vincent T, Hall J, Roberts K, Collins R, Mullighan C, Hunger S, Willman C, Loh M, et al: Targeting JAK2 and mTOR in xenograft models of CRLF2-overexpressing Acute Lymphoblastic Leukemia (ALL). Pediat Blood Cancer. 58:1014. 2012.
4	Tasian SK, Maude SL, Hall J, Vincent T, Mullighan CG, Willman CL, Hunger S, Loh ML, Teachey DT and Grupp SA: In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL). J Clin Oncol. 9506:2012.
5	Krawczyk J, Haslam K, Lynam P, Kelly J, Storey L, O'Marcaigh A, Langabeer SE and Smith OP: No prognostic impact of P2RY8-CRLF2 fusion in intermediate cytogenetic risk childhood B-cell acute lymphoblastic leukaemia. Br J Haematol. 160:555–556. 2013. View Article : Google Scholar : PubMed/NCBI
6	Francis OL: TSLP-induced mechanisms and potential therapies for CRLF2 B-cell acute lymphoblastic leukemia. Dissertations Theses-Gradworks. Loma Linda University Electronic Theses, Dissertations & Projects. 282:2015.
7	Maude SL, Tasian SK, Vincent T, Hall JW, Sheen C, Roberts KG, Seif AE, Barrett DM, Chen IM, Collins JR, et al: Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 120:3510–3518. 2012. View Article : Google Scholar : PubMed/NCBI
8	Chiaretti S, Brugnoletti F, Messina M, Paoloni F, Fedullo AL, Piciocchi A, Elia L, Vitale A, Mauro E, Ferrara F, et al: CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. Leuk Res. 41:36–42. 2016. View Article : Google Scholar : PubMed/NCBI
9	Konoplev S, Lu X, Konopleva M, Jain N, Ouyang J, Goswami M, Roberts KG, Valentine M, Mullighan CG, Bueso-Ramos C1, et al: CRLF2-positive B-cell acute lymphoblastic leukemia in adult patients: A single-institution experience. Am J Clin Pathol. 147:357–363. 2017. View Article : Google Scholar : PubMed/NCBI
10	Dou H, Chen X, Huang Y, Su Y, Lu L, Yu J, Yin Y and Bao L: Prognostic significance of P2RY8-CRLF2 and CRLF2 overexpression may vary across risk subgroups of childhood B-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. 56:135–146. 2017. View Article : Google Scholar : PubMed/NCBI
11	Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, Ricci F, Tazzari PL, Pagliaro P, McCubrey JA, et al: Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia. 28:739–748. 2014. View Article : Google Scholar : PubMed/NCBI
12	Tasian SK, Teachey DT, Li Y, Shen F, Harvey RC, Chen IM, Ryan T, Vincent TL, Willman CL, Perl AE, et al: Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 129:177–187. 2017. View Article : Google Scholar : PubMed/NCBI
13	Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, Locatelli F, Cazzaniga G, Niggli F, Aricò M, et al: Dexamethasone vs prednisone in induction treatment of pediatric ALL: Results of the randomized trial AIEOP-BFM ALL 2000. Blood. 127:2101–2112. 2016. View Article : Google Scholar : PubMed/NCBI
14	Zhang B, Suer S, Livak F, Adediran S, Vemula A, Khan MA, Ning Y and Hussain A: Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells. Mol Pharmacol. 82:310–321. 2012. View Article : Google Scholar : PubMed/NCBI
15	Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, et al: Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: A report of four patients. Haematologica. 102:e514–e517. 2017. View Article : Google Scholar : PubMed/NCBI
16	Sadras T, Heatley SL, Kok CH, Dang P, Galbraith KM, McClure BJ, Muskovic W, Venn NC, Moore S, Osborn M, et al: Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Lett. 408:92–101. 2017. View Article : Google Scholar : PubMed/NCBI
17	Francis OL, Shiraz P, Milford TA, Baez I, Coats JS, Mayagoitia K, Ginelli E, Salcedoconcepcion KR, Martinez S, Zhang X, et al: Abstract 3295: A novel patient-derived xenograft model for evaluating the role of TSLP in CRLF2 B-ALL. Cancer Res. 75:3295. 2015. View Article : Google Scholar
18	Herold T, Schneider S, Metzeler KH, Neumann M, Hartmann L, Roberts KG, Konstandin NP, Greif PA, Bräundl K, Ksienzyk B, et al: Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Haematologica. 102:130–138. 2017. View Article : Google Scholar : PubMed/NCBI
19	Stoian C, Mambo NG, Mccarthy P, Vidales V, Coats JS, Baez I, Dovat S, Gohar SF, Desai D, Kamal M and Payne KJ: Abstract 5829: Targeting TSLP-induce upregulation of Mcl-1 for the treatment of Ph-like ALL with CRLF2 alterations. Cancer Res. 77:5829. 2017. View Article : Google Scholar
20	Shi C, Han L, Tabe Y, Mu H, Wu SC, Zhou J, Zeng Z, Fruman DA, Tasian SK, Weinstock DM and Konopleva M: Dual targeting of JAK2 signaling with a type II JAK2 inhibitor and of mTOR with a TOR kinase inhibitor induces apoptosis in CRLF2-rearranged Ph-like acute lymphoblastic leukemia. Blood. 124:37062014.
21	Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO, et al: Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget. 9:8027–8041. 2018.PubMed/NCBI
22	Francis OL, Milford TA, Martinez SR, Baez I, Coats JS, Mayagoitia K, Concepcion KR, Ginelli E, Beldiman C, Benitez A, et al: A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis. Haematologica. 101:417–426. 2016. View Article : Google Scholar : PubMed/NCBI
23	Lane AA, Bodegom DV, Chapuy B, Alexe G, Sullivan TJ, Tivey T, Day T, Crispino J, Fox E, Stegmaier K and Weinstock D: Trisomy of the down syndrome critical region suppresses precursor B-cell differentiation and promotes B-cell transformation associated with altered expression of polycomb repressor complex 2 targets. Blood. 120:1152012.
24	Raghunathan R, Mahesula S, Kancharla K, Janardhanan P, Jadhav YL, Nadeau R, Villa GP, Cook RL, Witt CM, Gelfond JA, et al: Anti-CRLF2 antibody-armored biodegradable nanoparticles for childhood B-ALL. Part Part Syst Charact. 30:355–364. 2013. View Article : Google Scholar : PubMed/NCBI